INGN 241 Demonstrates Anticancer Activity Through PKR Binding and Bystander Killing

Strategic Insights -

Preclinical studies have identified the molecular pathways by which mda-7, the active component of INGN 241, induces growth arrest and programmed cell death (apoptosis) in cancer cells. Researchers at Introgen Therapeutics, Inc., and The University of Texas M. D. Anderson Cancer Center have found that MDA-7 protein binds to a critical cellular enzyme called PKR, essential for the anticancer activity of INGN 241. This discovery demonstrates a significant advancement in understanding how this therapeutic can be effective against cancer.

Key Takeaways:

  • MDA-7 protein binds to PKR, a critical cellular enzyme, essential for the anticancer activity of INGN 241.
  • INGN 241 induces cell death through two independent mechanisms in pancreatic cancer cells, including bystander killing of neighboring cancer cells by secreted MDA-7 protein.
  • The binding of MDA-7 to PKR is essential for the anticancer activity of INGN 241, indicating a significant advancement in understanding how this therapeutic can be effective against cancer.
  • The MDA-7 protein produced by INGN 241 physically interacts with PKR protein, and both proteins are phosphorylated, altering the activity of PKR and resulting in apoptosis in lung cancer cells.
  • Phosphorylation of MDA-7 is important for its activity, and the identification of the first known binding protein for MDA-7 indicates that phosphorylation of MDA-7 is crucial for its function.
  • INGN 241 also triggers apoptosis and cell death in pancreatic cancer cells via the IL-20 receptor on neighboring cells.
  • The mda-7 gene was discovered by the laboratory of Dr. Paul B. Fisher, and Introgen holds an exclusive worldwide license for all gene therapy applications from the Corixa Corporation.
  • INGN 241 is currently being evaluated in a phase 2 trial in patients with malignant melanoma.

Statistics:

  • 85% of pancreatic cancer patients survive less than a year after diagnosis (Source: American Cancer Society).
  • INGN 241 induces time- and dose-dependent induction of PKR in lung cancer cells (Source: Introgen Therapeutics, Inc.).
  • The PKR enzyme is phosphorylated, altering the function of cell and virus proteins (Source: Introgen Therapeutics, Inc.).
  • Phosphorylation of MDA-7 is important for its activity, and phosphorylated MDA-7 binds to PKR protein (Source: Introgen Therapeutics, Inc.).

Sources:

  • Health & Medicine Week editors, "Preclinical Data Reported for INGN 241"
  • NewsRx.com, "Health & Medicine Week" (Copyright 2005)
  • Introgen Therapeutics, Inc., press release, "Introgen Therapeutics, Inc. Announces Positive Preclinical Data for INGN 241"